BR112018016300A2 - fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso - Google Patents
fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenosoInfo
- Publication number
- BR112018016300A2 BR112018016300A2 BR112018016300A BR112018016300A BR112018016300A2 BR 112018016300 A2 BR112018016300 A2 BR 112018016300A2 BR 112018016300 A BR112018016300 A BR 112018016300A BR 112018016300 A BR112018016300 A BR 112018016300A BR 112018016300 A2 BR112018016300 A2 BR 112018016300A2
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes
- vitiligo
- gout
- acne
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
trata-se de um composto especificado pela fórmula (i), em particular, dimetilfumarato (éster dimetílico de ácido trans-1,2-etilenodicarboxílico) fornecido para uso na prevenção ou na terapia de gota, acne, pioderma gangrenoso, vitiligo, doença cardiovascular, síndrome metabólica, diabetes e/ou complicações de diabetes. também são fornecidos uma forma de dosagem que compreende o dito composto e um método de tratamento que compreender administrar o dito composto a um paciente em necessidade do mesmo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16155554 | 2016-02-12 | ||
EP16175524 | 2016-06-21 | ||
EP16177215 | 2016-06-30 | ||
EP16202534 | 2016-12-06 | ||
PCT/EP2017/053029 WO2017137576A1 (en) | 2016-02-12 | 2017-02-10 | Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018016300A2 true BR112018016300A2 (pt) | 2018-12-26 |
Family
ID=58018104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018016300A BR112018016300A2 (pt) | 2016-02-12 | 2017-02-10 | fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190029987A1 (pt) |
EP (1) | EP3413884A1 (pt) |
JP (1) | JP2019510743A (pt) |
AU (1) | AU2017216861A1 (pt) |
BR (1) | BR112018016300A2 (pt) |
WO (1) | WO2017137576A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3956342A4 (en) * | 2019-02-15 | 2023-05-24 | Triterpenoid Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR INHIBITION OF NLRP3 INFLAMMOSOME AND/OR LON PROTEASE |
CN110169571A (zh) * | 2019-05-28 | 2019-08-27 | 沈阳抗风竤生物技术有限公司 | 用于提高生育能力的食疗组合物 |
KR20220133807A (ko) * | 2021-03-25 | 2022-10-05 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
JP5232658B2 (ja) * | 2006-02-15 | 2013-07-10 | エムディー バイオアルファ カンパニー リミテッド | オキシドレダクターゼによるnad(p)/nad(p)h比を制御するための方法 |
EP2731971A1 (en) * | 2011-07-12 | 2014-05-21 | Universität Zürich | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
EA201600457A1 (ru) * | 2013-12-12 | 2016-11-30 | Альмираль, С.А. | Фармацевтические композиции, содержащие диметилфумарат |
CN105769594A (zh) * | 2014-12-26 | 2016-07-20 | 罗继琴 | 一种治疗小面积白癜风的化妆品 |
TW201705961A (zh) * | 2015-06-11 | 2017-02-16 | 阿爾米雷爾有限公司 | 作為jak抑制劑的2-(吡唑并吡啶-3-基)嘧啶衍生物 |
-
2017
- 2017-02-10 BR BR112018016300A patent/BR112018016300A2/pt not_active IP Right Cessation
- 2017-02-10 AU AU2017216861A patent/AU2017216861A1/en not_active Abandoned
- 2017-02-10 WO PCT/EP2017/053029 patent/WO2017137576A1/en active Application Filing
- 2017-02-10 US US16/077,476 patent/US20190029987A1/en not_active Abandoned
- 2017-02-10 JP JP2018542201A patent/JP2019510743A/ja active Pending
- 2017-02-10 EP EP17704749.5A patent/EP3413884A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20190029987A1 (en) | 2019-01-31 |
AU2017216861A1 (en) | 2018-10-04 |
JP2019510743A (ja) | 2019-04-18 |
WO2017137576A1 (en) | 2017-08-17 |
EP3413884A1 (en) | 2018-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI202100014A (es) | Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
CL2014000428A1 (es) | Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica. | |
GT201700143A (es) | Derivado de biarilo como agonista de gpr120 | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
AR091089A1 (es) | Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada | |
BR112012032579A2 (pt) | "terapia de diabetes" | |
AR088983A1 (es) | Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
BR112018016300A2 (pt) | fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso | |
WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
BR112014011223A2 (pt) | método de tratar uma doença proliferativa | |
BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
CO2017005203A2 (es) | Acido benzoico, derivados de acido benzoico y conjugados de acido carboxilico de heteroarilo de oximorfona, profarmacos, metodos de fabricacion y uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2556 DE 31/12/2019. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |